Frontlight ResearchEarly access
Taking people in United StatesPhase 1/2
Tests RMC-6236 in advanced solid tumors with certain RAS gene mutations
Tests RMC-6236 in adults with advanced solid tumors that have certain RAS mutations.
Key facts
- Who runs it
- Revolution Medicines, Inc.
- Where
- Atlanta, Austin, Baltimore, Baton Rouge, Boston, Chattanooga, Cincinnati, Dallas, Fairfax, Houston, Maumee, Nashville, New York, Orange, Salt Lake City, San Antonio, Santa Monica, Seattle, and Tampa, United StatesSee the 21 sites
- Trial code
- Registry title
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 754 people, planned
- Started
- 31 May 2022
- Expected to end
- 26 Jul 2027
- Type of study
- Interventional
- Treatments tested
- RMC-6236
- Record updated
- 15 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors that carry certain RAS gene changes. It tests the safety of the drug RMC-6236.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced solid tumor confirmed by tissue tests, with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion). Pancreatic cancer (PDAC) with wild-type RAS is also included in the expansion part.
- Earlier treatment
- People can join if they have had no treatment yet, or if they have had prior standard therapy appropriate for their tumor type and stage.
- Biomarker or test result
- Specific KRAS G12 mutations or RAS mutations found by DNA sequencing. Wild-type RAS for PDAC in the expansion part.
Main reasons for not taking part
- Primary tumor of the central nervous system (CNS)
- Active brain metastases that have not been treated
- Stomach or bowel problems that make it hard to swallow or absorb an oral medicine
- Another unstable or serious medical condition that the investigator thinks could harm safety or affect taking part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion)
- Treatment naive or have received prior standard therapy appropriate for tumor type and stage
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
Who cannot take part
- History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy; Other inclusion/exclusion criteria may apply
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- Primary central nervous system (CNS) tumors
- Active, untreated brain metastases
Where in United States
- Piedmont HealthcareAtlanta, United StatesContact: Revolution Medicines, Inc.Taking people
- University of Texas at AustinAustin, United StatesContact: Revolution Medicines, Inc.Taking people
- Johns Hopkins UniversityBaltimore, United StatesContact: Revolution Medicines, Inc.Taking people
- Mary Bird Perkins Cancer CenterBaton Rouge, United StatesContact: Revolution Medicines, Inc.Taking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: Revolution Medicines, Inc.Taking people
- Tennessee OncologyChattanooga, United StatesContact: Revolution Medicines, Inc.Taking people
- Christ Hospital Cancer CenterCincinnati, United StatesContact: Revolution Medicines, Inc.Taking people
- Mary Crowley Cancer ResearchDallas, United StatesContact: Revolution Medicines, Inc.Taking people
- NEXT Oncology- VirginiaFairfax, United StatesContact: Revolution Medicines, Inc.Taking people
- The University of Texas MD Anderson Cancer CenterHouston, United StatesContact: Revolution Medicines, Inc.Taking people
- Taylor Cancer Research CenterMaumee, United StatesContact: Revolution Medicines, Inc.Taking people
- Sarah Cannon Research InstituteNashville, United StatesContact: Revolution Medicines, Inc.Taking people
- Columbia UniversityNew York, United StatesContact: Revolution Medicines, Inc.Taking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Revolution Medicines, Inc.Taking people
- Perlmutter Cancer Center at NYU Langone HealthNew York, United StatesContact: Revolution Medicines, Inc.Taking people
- UC Irvine/Chao Family Comprehensive Cancer CenterOrange, United StatesContact: Revolution Medicines, Inc.Taking people
- Huntsman Cancer InstituteSalt Lake City, United StatesContact: Revolution Medicines, Inc.Taking people
- NEXT OncologySan Antonio, United StatesContact: Revolution Medicines, Inc.Taking people
- UCLASanta Monica, United StatesContact: Revolution Medicines, Inc.Taking people
- Virginia Mason Medical CenterSeattle, United StatesContact: Revolution Medicines, Inc.Taking people
- Moffitt Cancer CenterTampa, United StatesContact: Revolution Medicines, Inc.Taking people
About the trial
What the trial wants to find out
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
The group in the trial
- Experimental: RMC-6236Treatment being tested
Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations. Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Treatment: RMC-6236
Results explained
Papers that name this trial, each explained in plain words.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Plain-language title
- Tests RMC-6236 in advanced solid tumors with certain RAS gene mutationsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.The New England journal of medicine, 2026
- Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.The New England journal of medicine, 2026
- Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.Cancer discovery, 2024
- Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Nature, 2024
- Record updated
- 15 May 2026